Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Article  CAS  PubMed  Google Scholar 

Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008.

Article  PubMed  Google Scholar 

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15.

Article  CAS  PubMed  Google Scholar 

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.

Article  CAS  PubMed  Google Scholar 

Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2022;42(2):227–37.

Article  CAS  PubMed  Google Scholar 

Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol. 2018;12(3):674-84.e5.

Article  PubMed  Google Scholar 

Cardner M, Yalcinkaya M, Goetze S, Luca E, Balaz M, Hunjadi M, et al. Structure-function relationships of HDL in diabetes and coronary heart disease. JCI Insight. 2020;5(1).

Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758–67.

Article  PubMed  PubMed Central  Google Scholar 

Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–22.

Article  CAS  PubMed  Google Scholar 

Rohatgi A, Westerterp M, von Eckardstein A, Remaley A, Rye KA. HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. Circulation. 2021;143(23):2293–309.

Article  PubMed  PubMed Central  Google Scholar 

Bonizzi A, Piuri G, Corsi F, Cazzola R, Mazzucchelli S. HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity. Biomedicines. 2021;9(7):729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116(12):3090–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1(2):121–31.

Article  CAS  PubMed  Google Scholar 

Jiang XC. Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis. J Lipid Res. 2018;59(5):764–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996;98(10):2373–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103(6):907–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160–7.

Article  CAS  PubMed  Google Scholar 

Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387(6631):414–7.

Article  CAS  PubMed  Google Scholar 

Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A. 1997;94(23):12610–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebtehaj S, Gruppen EG, Bakker SJL, Dullaart RPF, Tietge UJF. HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population. Arterioscler Thromb Vasc Biol. 2019;39(9):1874–83.

Article  CAS  PubMed  Google Scholar 

Akinmolayemi O, Saldanha S, Joshi PH, Deodhar S, Ayers CR, Neeland IJ, et al. Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study). PLoS ONE. 2021;16(9): e0257574.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3(7):507–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apro J, Tietge UJ, Dikkers A, Parini P, Angelin B, Rudling M. Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report. Arterioscler Thromb Vasc Biol. 2016;36(5):787–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed MO, Byrne RE, Pazderska A, Segurado R, Guo W, Gunness A, et al. HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study. Diabetologia. 2021;64(3):656–67.

Article  CAS  PubMed  Google Scholar 

de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia. 2005;48(6):1105–13.

Article  CAS  PubMed  Google Scholar 

Emmens JE, Jia C, Ng LL, van Veldhuisen DJ, Dickstein K, Anker SD, et al. Impaired High-Density Lipoprotein Function in Patients With Heart Failure. J Am Heart Assoc. 2021;10(9): e019123.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hunjadi M, Lamina C, Kahler P, Bernscherer T, Viikari J, Lehtimäki T, et al. HDL cholesterol efflux capacity is inversely associated with subclin